Skip to content

Meet us at COP31Read more

Shenzhen Hepalink Pharmaceutical Group Co Ltd Sustainability Reports

The company operates across the entire industrial chain of heparin, providing heparin API and biosimilar enoxaparin sodium injections globally. It also offers comprehensive CDMO services for large biological molecules and invests in innovative drug development.

Sector: Manufacturing

Country: China

Exchange: Shenzhen Stock Exchange

FIGI: BBG001T6M6Z6

13 reports from 2020 to 2025